One small step for stool, one giant leap for IBD surveillance

Area of Science:

• Gastroenterology
• Microbiology
• Biotechnology

Background:

• Inflammatory bowel diseases (IBD) involve chronic, relapsing inflammation of the digestive tract, leading to severe symptoms like pain, bleeding, and diarrhea.
• Current surveillance methods for IBD can be invasive and costly, hindering timely detection of disease flares.
• There is a need for noninvasive, economical methods to monitor gut inflammation and improve the quality of life for IBD patients.

Purpose of the Study:

• To develop an innovative, cost-effective, and noninvasive method for dynamically monitoring inflammation within the mammalian gastrointestinal tract.
• To engineer a rationally designed *Escherichia coli* strain capable of distinguishing between dormant and active inflammatory states in the gut.
• To demonstrate the potential of engineered probiotics as living biosensors for real-time health status monitoring in inflammatory diseases.

Main Methods:

• Design and engineering of a specific *Escherichia coli* strain as a probiotic biosensor.
• In vivo testing of the engineered *E. coli* to assess its ability to monitor inflammation in the gastrointestinal tract.
• Evaluation of the biosensor's capacity to differentiate between varying inflammatory states within the gut.

Main Results:

• Successful development of an engineered *Escherichia coli* strain for dynamic inflammation monitoring.
• Demonstration of the probiotic's ability to specifically discern between dormant and activated inflammatory states.
• Proof of concept for using living biosensors to monitor gut health status.

Conclusions:

• Engineered probiotics represent a novel and powerful tool for clinical diagnostics in inflammatory diseases.
• This approach offers a noninvasive and economical surveillance method for inflammatory bowel diseases.
• The development heralds a new era of smart biosensors for managing chronic gut conditions and improving patient outcomes.